| Literature DB >> 28441777 |
Elixabet Díaz-de-Cerio1,2, Vito Verardo3, Ana María Gómez-Caravaca4, Alberto Fernández-Gutiérrez5,6, Antonio Segura-Carretero7,8.
Abstract
Today, there is increasing interest in discovering new bioactive compounds derived from ethnomedicine. Preparations of guava (Psidium guajava L.) leaves have traditionally been used to manage several diseases. The pharmacological research in vitro as well as in vivo has been widely used to demonstrate the potential of the extracts from the leaves for the co-treatment of different ailments with high prevalence worldwide, upholding the traditional medicine in cases such as diabetes mellitus, cardiovascular diseases, cancer, and parasitic infections. Moreover, the biological activity has been attributed to the bioactive composition of the leaves, to some specific phytochemical subclasses, or even to individual compounds. Phenolic compounds in guava leaves have been credited with regulating blood-glucose levels. Thus, the aim of the present review was to compile results from in vitro and in vivo studies carried out with guava leaves over the last decade, relating the effects to their clinical applications in order to focus further research for finding individual bioactive compounds. Some food applications (guava tea and supplementary feed for aquaculture) and some clinical, in vitro, and in vivo outcomes are also included.Entities:
Keywords: Psidium guajava L. (guava) leaves; in vitro; in vivo; pharmacology; phenolic compounds; traditional medicine
Mesh:
Substances:
Year: 2017 PMID: 28441777 PMCID: PMC5412476 DOI: 10.3390/ijms18040897
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Main traditional uses of guava leaves in the principal producer countries.
In vitro assays against infectious and parasitic diseases.
| Origin | Extraction Method | Major Constituent | Microorganisms | Assay | Main Results | Ref. |
|---|---|---|---|---|---|---|
| Saudi Arabia | Decoction (30 min) | - | Agar well diffusion assay | At 200 µL: iz ≤ 30 mm. | [ | |
| India | Soxhlet with MeOH (12 h), maceration in H2O (4 h) | - | Agar well diffusion assay, time-kill of bacterial cell, SDS-PAGE analysis, and cellular toxicity to human erythrocytes assays | At 20 mg/L: iz ≤ 20 mm, MIC: 25 µg/mL (MeOH) and 7.5 mg/mL (H2O). MBC: 1.25 and 12.5 mg/mL, respectively, 10 h to kill bacteria, ↑ degradation of protein, no hemolysis. | [ | |
| Nigeria | Maceration in MeOH (48 h) | - | Agar well diffusion assay | At 20 mg/mL: iz ≤ 18 mm; 81.8% prevention growth. | [ | |
| India | Maceration with agitation in MeOH, Ac, and DMF (12 h) | - | G-p and G-n bacteria and fungi (91 clinically important strains) | Disc diffusion assay | At 25 mg/mL: against g-p 70% MeOH > 80% Ac > 50% DE, ↓ 76.36% g-n bacteria. Fungi 56% Ac > 38% ME > 31% DMF. No activity against | [ |
| India | Soxhlet with MeOH (4 h) | Phytochemical screening: mainly flavonoid-glycosides and tannins | Bacteria ( | Paper disc diffusion assay | At 50 μg/mL: iz ≤ 12.6 mm and 10 mm for bacterial and fungi strains, respectively. | [ |
| Brazil | Maceration with stirring in EtOH:H2O 70% ( | TPC: 25.93 (% m/m, dry base), TFC: 23.48 (mg/g, dry base) | Fungi ( | Microdilution assay | MIC = 80–100 µg/mL ( | [ |
| Brazil | Turbo-extraction with water or Ac:H2O 70% ( | Gallic acid: 0.065 µg/g, Catechin: 1.04 µg/g | G-p strains ( | Agar-diffusion and microdilution assays | At 5 mg/mL: iz ≤ 20 mm, MIC = 39 μg/mL ( | [ |
| India | Soxhlet with n-hexane | Methyl 2,6,10-trimethyltridecanoate (28.86%) and Methyl octadecanoate (22.18%) | G-p: | Agar well diffusion assay | At 80 µL: iz ≤ 27 mm, MIC = 3–10 µL. | [ |
| Brazil | Maceration in EtOH:H2O 70% ( | - | Microdilution assay | Only | [ | |
| Brazil | Maceration in MeOH:H2O 70% ( | - | Disc diffusion assay | MIC 90% = 0.52 mg/mL, at 131.75 mg/mL synergic effect with tetracycline, chloramphenicol, erythromycin, vancomycin, oxacillin, cephalothin, ampicillin, cefoxitin, cotrimoxazole. | [ | |
| Egypt | Maceration in EtOH:H2O 50% ( | Quercetin, avicularin, guajaverin, isoquercitrin, hyperin | Agar well diffusion assay | [ | ||
| Indonesia | Maceration in EtOH:H2O 30% ( | Tannins (2.35 mg/g) | Paper disc diffusion method | iz ≤ 15 mm. | [ | |
| India | Soxhlet with toluene (72 h) | Betulinic acid and lupeol | Fungi: | Slide germination method | Bacteria: MIC < 100–200 μg/mL, fungi: MIC < 2.5–10 μg/mL. | [ |
| India | Soxhlet with Ac (8 h) | - | Antiparasitic activity method of FAO (2004) | At 3 mg/mL: mortality 100% | [ | |
| Nigeria | Maceration with agitation in EtOH:H2O 20% and 80% ( | - | Alamar Blue assays | At 238.10 μg/mL: IC50 ( | [ | |
| India | Soxhlet with ethyl acetate and MeOH (8 h) | - | SYBR green assay | IC50 9–18 μg/mL, resistance indices = 0.6 and 1.4 in MeOH and ethyl acetate, respectively. | [ | |
| Malaysia | Hydrodistillation (3 h) | - |
| MTT assay with Vero cells | At 200 µg/mL: No cytotoxic effect (EC50 = 37.54 µg/mL), anti-parasitic activity (EC50 of 3.94 µg/mL). | [ |
| India | Soxhlet with EtOH, and maceration in H2O (6 days) | - | Agar well diffusion assay | H2O: iz ≤ 30 mm (max | [ | |
| India | Soxhlet with EtOH:H2O 70% ( | Phytochemical analysis: tannins, saponins, flavonoids, terpenoids, sugars | Agar well diffusion assay | At 1000 µg/mL: iz ≤ 30 mm. MeOH: MIC (100%) > 250 µg/mL. EtOH:H2O:MICs (38–65%) > 500 µg/mL and > 750 µg/mL. Ethyl acetate and H2O: MICs > 750 µg/mL. | [ | |
| Bangladesh | Maceration in H2O and MeOH:H2O 75% ( | - |
| Agar well diffusion assay | MICs = 1250 µg/mL (H2O), 850 µg/mL for (MeOH:H2O). Antibacterial resistance to trimethoprim/sulfomethoxazole, furazolidone, tetracycline, and erythromycin. | [ |
| India | Decoction | Major component: quercetin (2 mg/g) | Microtitre plate based assay. Assays for bacterial colonization (adherence and invasion) and enterotoxins | At 2.7 mg/mL: (EC50 = 0.98 ( | [ | |
| Brazil | Soxhlet with n-hexane, ethyl acetate, MeOH, H2O (24 h) | - | Disc diffusion method | At 1938 µg/disc: iz = 7.00–11.25 mm (Soxhlet), and 11–18 mm (H2O). No inhibition to | [ | |
| Nigeria | Soxhlet with EtOH:H2O 60% ( | - | Agar well diffusion assay | At 10 mg/mL: H2O: iz = 9–16 mm and 8–11 mm, MICs = 5 and 2.5 mg/mL ( | [ | |
| Japan | Infusion (8 min) | Tannin content: 1.11 mg/mL | H1N1 virus strains | 19-h Influenza growth inhibition assay | At 0.4 mg/mL: inhibition growth (IC50 = 0.05–0.42%). | [ |
Acetone (Ac); N,N-dimethylformamide (DMF); dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE); effective concentration (EC50); inhibition zone (iz); inhibitory concentration (IC50); lethal concentration (LC50); minimum bactericidal concentration (MBC); minimum fungicidal concentration (MFC); minimum inhibitory concentration (MIC); total flavonoid content (TFC); total phenolic content (TPC); Tetrazolium (MTT); ↑ increases the affect; ↓ decreases the effect.
In vitro studies against neoplasm.
| Origin | Extraction Method | Major Constituent | Cell Line | Assay | Main Results | Ref. |
|---|---|---|---|---|---|---|
| Japan | Maceration in EtOH:H2O 50% ( | TPC: 71 g/100 g | Human colon adenocarcinoma (COLO320DMA) | Cyclooxygenase and cell proliferation assays | At 1 mg/mL: ↓ human cyclooxygenase activity (IC50 55 and 560 µg/mL PGHS-1 and 2, respectively), ↓ IC50 5.1 µg/mL (PGSH) and 4.5 µg/mL (cyclooxygenase). | [ |
| At 100 µg/mL: Quercetin ↓ IC50 = 5.3 (PGSH-1) and 250 µg/mL (PGSH-2), ↓ DNA synthesis rate. | ||||||
| Malaysia | Soxhlet with ether, MeOH, and H2O | - | Cervical cancer (HeLa), breast cancer (MDA-MB-231) and osteosarcoma (MG-63). Control: non-malignant Madin-Darby canine kidney (MDCK) | Methylene blue assay | At 10 mg/mL: HeLa: No anti-proliferative activity. | [ |
| MDA-MB-231: IC50 ether extract (4.2 µg/mL) > MeOH (18.6 µg/mL) > H2O (55.7 µg/mL). | ||||||
| MG-63: same order (IC50 of 5.42, 23.25, and 61.88 µg/mL, respectively). | ||||||
| MDCK: cytotoxic effect of ether and MeOH extract (IC50 = 5.03 and 11.55 µg/mL, respectively). | ||||||
| Brazil | Maceration in EtOH | TPC: 766.08 mg/g, TFC: 118.90 mg/g | HeLa, colorectal carcinoma (RKO-AS45-1), and lung fibroblast (Wi-26VA4) | MTT assay | At 1 mg/mL: IC50 = 15.6 µg/mL (HeLa), 21.2 (RKO) µg/mL, and 68.9 µg/mL (Wi-26VA4). | [ |
| Palestine | Maceration in DCM:MeOH 50% ( | - | Murine fibrosarcoma (L929sA), and human breast cancer (MDA-MB-231 and MCF-7) | MTT assay | IC50 = 55 µg/mL (L929sA), 820 µg/mL (MCF7 cells), no cytotoxic effect on MDA-MB-231 cells. | [ |
| Taiwan | Decoction (30 min) | - | Human prostate carcinoma (DU-145) | MTT, ELISA, gelatinolytic zymography, wound scratch, and chicken chorioallantoic membrane assays | At 0.25 mg/mL: cell suppression (IC50 0.57 mg/mL). ↓ Expressions of VEGF (76.9%), IL-6 (98.8%) and IL-8 (98%), and MMP-2 (100%) and MMP-9 (100%). Suppressed the cell migration (30.9%) and the angiogenesis. | [ |
| Taiwan | Decoction (1 h) | TPC: 470.0 mg/g Individual compounds: gallic acid (348), catechin (102), epicatechin (60), rutin (100), quercetin (102), and rutin (100) in mg/g | Human prostate epithelial (PZ-HPV-7) and DU-145 | MTT assay | At 1 mg/mL: 100% suppression DU-145 cells. PZ-HPV-7 cells followed an auto-decaying process. Cell-killing rate coefficient (kapp) = 0.03 × 103 phenolic compounds cells/mg h. | [ |
| Brazil | Soxhlet with DCM. Maceration with EtOH | Guajadial, psidial A, and psiguajadial A and B | Leukemia (K-562), MCF-7, ovarian cancer (NCI/ADR-RES), lung (NCI-H460), melanoma (UACC-62), prostate (PC-3), colon (HT-29), ovarian (OVCAR-3), and kidney (786-0) | Protocol established by NCI (ELISA test) | At 250 µg/mL: Anti-proliferative activity DCM > EtOH, inhibition growths: 26 (OVCAR-3)-65 (UACC-62) µg/mL due to the major compounds. | [ |
| Japan | Maceration with sonication in MeOH:H2O 80% ( | CPO | PC-3 and MCF-7 | MTT, annexin V antibody, TUNEL, and western blot assays | At 50 µg/mL: ↓ cell proliferation, ↑ early and late apoptotic effect, down-regulation of PI3K/AKT/mTOR/S6K1 pathway, up-regulation of MAPKs, JNK, ERKs, and p38 MAPK. | [ |
| Thailand | Hydrodistillation | Human mouth epidermal carcinoma (KB) and murine leukemia (P388) | MTT assay | At 0.15 mg/mL: KB: 75% cytotoxic effect, IC50 = 0.04 mg/mL; At 0.08 mg/mL: P388: 80% cytotoxic effect, IC50 = 0.05 mg/mL. | [ | |
| Jamaica | Maceration in hexane (4 days) | - | Leukemia (Kasumi-1) | MTT assay | IC50 = 200 µg/mL. | [ |
| Japan | Maceration with sonication in MeOH:H2O 80% ( | 60 compounds (in hexane fraction): β-eudesmol (11.98%), α-copaene (7.97%), phytol (7.95%), α-patchoulene (3.76%), and CPO (3.63%) | Human prostate cancer (PC-3 and LNCaP) | MTT, annexin V antibody, TUNEL, and western blot assays | At 150 µg/mL: PC-3: ↑ apoptotic effect of the hexane fraction (15%), ↓ effect on early apoptotic cells, ↑ effect for late apoptosis, via the suppression of PI3K/AKT/mTOR/S6K1 and MAPK signalling cascades in both cell lines. | [ |
β-Caryophyllene oxide (CPO); c-jun NH2-terminal kinases (JNK); dichloromethane (DCM); inhibitory concentration (IC50); mammalian target of rapamycin (mTOR); mitogen-activated protein kinases (MAPKs); phosphatidylinositol 3-kinase (PI3K); prostaglandin endoperoxide H synthase (PGHS); protein kinase B (AKT); ribosomal protein S6 kinase beta-1 (S6K1); signal-related kinases (ERKs); tetrazolium (MTT); total flavonoid content (TFC); total phenolic content (TPC); ↑ increases the affect; ↓ decreases the effect.
In vitro assays against diseases of the blood and immune system.
| Origin | Extraction Method | Major Constituent | Cells | Assay | Main Results | Ref. |
|---|---|---|---|---|---|---|
| Korea | Maceration in MeOH:H2O 70% ( | - | LPS-stimulated RAW 264.7 (Mouse macrophage) | Griess, MTT, ELISA kit, western blot, transient transfection, and luciferase assays | At 125 µg/mL: no cytotoxic effect, ↑ 44–62% inhibition rates. ↓ LPS-induced NO and PEG2 ↓ iNOS and COX-2 (↓ I-κBα degradation, ↓ activation NF-κB). | [ |
| Palestine | Maceration in DCM:MeOH 50% ( | - | L929sA fibroblast | Transfection and luciferase assays | At 62.5 µg/mL: ↓ expression of IL-6 and NF-κB luciferase reporter gene construct via the NF-κB transactivation level, since no ↓ inhibition of NF-κB/DNA binding. | [ |
| Korea | Extraction in MeOH:H2O 70% ( | TPC: 426.84 mg (GAE)/g | LPS-stimulated RAW 264.7 | MTT, Griess, and ELISA test assays | At 30 µg/mL: no cytotoxic effect. ↓ LPS-induced NO (52.58%) and the production of PGE2 (43.45). | [ |
| Korea | Extraction in EtOH:H2O 55% ( | Gallic acid (0.2) and catechin (4.4) in mg/g | LPS-stimulated RAW 264.7 | MTT, Griess, ELISA test, RT-PCR, and total western blot assays | At 50 µg/mL: no cytotoxic effect. ↓ LPS-induced NO (>65%) by ↓ iNOS, ↓ PGE2 (to basal level) via ↓ COX-2 mRNA. ↓ IL-6. ↓ iNOS and COX-2 due to the down-regulation of ERK1/2 pathway, because no effect was found to other proteins at the dose tested. | [ |
| India | Maceration in MeOH:H2O 90% ( | - | LPS-stimulated in Labeo rohita head-kidney macrophages | MTT, Greiss, ELISA, RT-PCR, and western blot assays | At 200 µg/mL, ↓ LPS-induced NO (75%) by ↓ iNOS-mRNA, ↓ PGE2 (45%) via ↓ production COX-2-mRNA, TNF-α, IL-1β, IL-10, and mRNA expression. Suppressed phosphorylation of MAPK (↓ I-κBα degradation ↓ activation NF-κB). | [ |
| Korea | Soxhlet with EtOH:H2O 55% ( | Gallic acid (0.09) and catechin (0.72) in mg/g | LPS-stimulated RAW 264.7 | MTT, Greiss and ELISA test assays | At 30 µg/mL: no cytotoxic effect. ↓ LPS-induced NO (47.5%) and PGE2 (45.8). | [ |
| India | Maceration with agitation in MeOH and EtOH (24 h) | - | Human blood | HRBC membrane stabilization method | At 200 µg/mL: ↑ 13.8–14.4% prevention of lysis of the membrane. | [ |
| Indonesia | Maceration with agitation in EtOH:H2O 96% ( | TPC: 101.93 mg GAE/g | Human lymphocyte | MTT assay | 0.5 μg/mL: Stimulation index 1.54%. | [ |
Cyclooxygenase-2 (COX-2); dichloromethane (DCM); gallic acid equivalent (GAE); human red blood cell (HRBC); inducible nitric oxide synthase (iNOS); inhibitor of kappa B (I-κBα); interleukin-1β (I-1β); lipopolysaccharide (LPS); mitogen-activated protein kinases (MAPKs); nitric oxide (NO); prostaglandin E2 (PEG2); reverse transcription-polymerase chain reaction RT-PCR; tetrazolium (MTT); total phenolic content (TPC); transcriptional nuclear factor-κB (NF-κB); Tumor necrosis factor alpha (TNF-α); ↑ increases the affect; ↓ decreases the effect.
Compounds in guava leaves with anti-diabetic properties in in vitro assays.
| Origin | Compound | Assay | Main Results | Ref. |
|---|---|---|---|---|
| India | Ethyl acetate fraction | In vitro glycation of BSA-fluorescence measurement | In vitro AGEs formation with IC50 of 38.95 ± 3.08 μg/mL. | [ |
| Taiwan | Gallic acid, catechin and quercetin | In vitro glycation of BSA-fluorescence measurement; Fructosamine assay and Girard-T assay | At 100 μg/mL: 80% inhibitory effects on the formation of α-dicarbonyl compounds at a concentration of 50 µg/mL, inhibitory effects on AGEs formation in BSA glycation systems. | [ |
| China | Quercetin, kaempferol, myricetin | Rat intestinal sucrase and maltase inhibitory activities; Porcine pancreatic α-amylase inhibitory activity | At 1.5 mg/mL: inhibitory activities with IC50 values of 3.5, 5.2 and 3.0 mM against sucrase, with IC50 values of 4.8, 5.6 and 4.1 mM against maltase and with IC50 values of 4.8, 5.3 and 4.3 mM against α-amylase, respectively. Synergistic effect against α-glucosidase. | [ |
| China | Water-soluble polysaccharides, including GP90 and P90 | α-Glucosidase inhibition assay | α-Glucosidase inhibition activity with an EC50 of 2.27 µg/mL and 0.18 mg/mL. | [ |
| - | Peltatoside, hyperoside, isoquercitrin, guaijaverin and flavonol-glycosides | Spectrophotometric assay; absorption assay into CaCo-2 cells | Concentration of the compounds (0.01 to 0.06 µmol/mL). Individual flavonol-glycosides inhibited DP-IV dose-dependently. The ethanolic guava leaves extract (380 µg/mL) showed a dose-dependent inhibition of DP-IV, with an IC50 of 380 μg/mL test assay solution; the highest uptake was from Guaijaverin. | [ |
| Korea | Quercetin and catechin | Fructose transport in CaCo-2 cell systems | At 1 mg/mL: inhibition of fructose uptake (55%). At 30 µg/mL: quercetin contributed to both, GLUT2 and 5 transporters, and catechin to GLUT5-mediated fructose uptake inhibition. | [ |
| India | Guavanoic acid | Spectrophotometric assay | At 27 μg/mL: remarkable PTP1B inhibitory activity (90%) and in vitro stability in various physiological medium including saline, histidine, cysteine, BSA, HSA and buffers (pH 5, 7 and 9). IC50 = 1.14 μg/mL. | [ |
| India | n-Hexane, methanol, ethanol and aqueous leaf extracts | Inhibitory glucose diffusion | At 50 g/L: the methanol extract was the most potent with the lowest mean glucose concentration of 201 ± 1.69 mg/dL at the end of 27 h (↓ 93% uptake). | [ |
| Japan | 70% Ethanol extract | Oil Red O Assay; Real-Time RT | At 100 μg/mL: inhibition of 3T3-L1 differentiation via down-regulation of adipogenic transcription factors and markers (mRNA levels of PPAR-γ, C/EBP-α, and aP2), and suppression of mitotic clonal expansion (at day 4 and 8). | [ |
| Taiwan | Aqueous extract | Glucose uptake test; bicinchonic acid method; Western-blot analysis | At 400 µg/mL: ↑ IR (25.1%), p-IR (46.2%), p-IRS (51.2%), PI3K (32.2%), Akt (46.1%), p-Akt (36.3%), GLUT-2 (46.8%), and total glycogen synthase (45.5%). | [ |
| Taiwan | Vescalagin | Glucose-uptake test | At 100 µg/mL: Enhancement of glucose uptake in TNF-α-induced insulin-resistant. | [ |
Advanced glycation end products (AGEs); bovine serum albumin (BSA), dipeptidyl peptidase (DP); effective concentration (EC50); glucose transporter 2 and 5 (GLUT-2; GLUT-5); human serum albumin (HSA); inhibitory concentration (IC50); insulin receptor (IR); insulin receptor substrate (p-IRS (Tyr)); p85 regulatory subunit of phospho-inositide 3 kinase (PI3K (p85)); phosphorylation of the insulin receptor (p-IR (Tyr)); protein kinase B (p-Akt (Ser)); tumor necrosis factor (TNF); ↓ decreases the effect.
In vitro assays against diseases related to the digestive system.
| Origin | Extraction Method | Microorganism(s)/Cells | Assay | Main Results | Ref. |
|---|---|---|---|---|---|
| India | Soxhlet with MeOH (4.5 h) | Agar well diffusion assay, effect on acid production, on sucrose-dependent adherence to smooth glass surfaces, and on sucrose-induced cellular aggregation, and MATH assays | MIC > 5 mg/mL (MeOH). MIC = 2–4 mg/mL (guaijaverin) | [ | |
| Malaysia | Decoction | NAM model system | At 60.95 mg/mL: MIC = 7.62 ( | [ | |
| Malaysia | Sonication with H2O (10 min) | MATH assay | At 1 mg/mL: ↓ 54.1%, 49.9% and 40.6%, respectively, cell-surface hydrophobicity. At 20 mg/mL: was 64.7, 60.5, and 55.5%, respectively. | [ | |
| Malaysia | Decoction | Bacterial growth and generation time rates determinations | At 4 mg/mL: Time growth = 1.22 ( | [ | |
| India | Maceration with stirring in EtOH (2 days) | Agar well diffusion assay | At 10 mg/mL: inhibition zones of 21.17, 18.58, and 23.00 mm, respectively. | [ | |
| India | Maceration (2 days) and Soxhlet (6 h) with EtOH, H2O, and EtOH:H2O 50% ( | Agar well diffusion assay, sucrose-dependent adherence and cellular co-aggregation activities, and biofilm formation sterile acrylic tooth determinations | At 15 mg/mL: inhibition zone for H2O (11.8 mm) to EtOH:H2O (25 mm), both by Soxhlet. MIC = 1 mg/mL. | [ | |
| India | Soxhlet with EtOH:H2O 50% ( | MATH assay | At >1 mg/mL ↓ hydrophobicity (index < 40%). | [ | |
| India | Maceration with stirring (2 days) and Soxhlet with EtOH | Agar well diffusion assay | At 10 mg/mL: ↑ inhibition zones for maceration extracts (19–23 mm). | [ | |
| Ghana | Maceration with agitation in EtOH:H2O 70% ( | Agar well diffusion assay, release of the cytosol enzyme lactate dehydrogenase, fluorescence assisted cell sorter, and ELISA assays | No growth inhibitory effect, although neutralized the cell death and pro-inflammatory response, and restored the morphological alterations induced by the leukotoxin. These effects were due to the direct binding of guava compounds and the leukotoxin. | [ | |
| India | Maceration in Ac, EtOH, chloroform, MeOH and H2O (15 days at 22 °C) | Agar well diffusion assay | ↑ Inhibition zones in Ac (15–29 mm), except for | [ | |
| India | Maceration in MeOH (72 h). Fractionation with ethyl acetate | HRBC membrane stabilization method, disc and agar well diffusion assays | MeOH and ethyl acetate fraction ↑ protection (84–99%) to the inflammatory response. Inhibition zones (25–100 µg/mL) = 10.5 to 22 mm by both methods. MICs = 0.48 (ethyl acetate) and 0.62 (MeOH) mg/mL. | [ | |
| Taiwan | Maceration EtOH, Ac, H2O (room temperature and 60 °C) (24 h) | Clone 9 rat liver cells | WST-1 and ALT assays | At >500 μg/mL cytotoxic effect of EtOH and Ac and 600 μg/mL for H2O. At <200 μg/mL normal values were observed for H2O and Ac, and EtOH (<500 μg/mL). | [ |
Alanin aminotransferase (ALT); colony forming unit (CFU); human red blood cell (HRBC); microbial adhesion to hydrocarbon test (MATH); minimum bactericidal concentration (MBC); minimum fungicidal concentration (MFC); minimum inhibitory concentration (MIC); nordini’s artificial mouth (NAM); Tetrazolium (WST-1); ↑ increases the affect; ↓ decreases the effect.
In vivo anti-bacterial effect.
| Origin | Extraction Method | Subject | Treatment | Main Results | Ref. |
|---|---|---|---|---|---|
| Thailand | Maceration in H2O, EtOH, and ether (24 h) |
|
| LD50 = 3.44 × 106 CFU/mL. ↓ Mortality of the subjects. | [ |
| China | - |
| Yellow-head virus, white spot syndrome virus, and | Survival rate = 80–95% (↑ Weight (2 to 6 g)). In serum (↑ feed): ↓ PO (7.50 U/mL) and SOD (178.33 U/mL), ↑ NOS (64.80 U/mL). In hepato-pancreas: ↑ SOD (57.32 U/mg), ACP (23.28 U/mg), AKP (19.35 U/mg), and LSZ (3459.946 U/mg). | [ |
| Nigeria | Maceration with agitation in EtOH:H2O 80% ( | Albino rats |
| At 300 mg/kg: ↓ parasitemia; ↑ survival in 24 days. | [ |
| Nigeria | Maceration with agitation in EtOH:H2O 80% ( | Albino rats |
| Administration 1–7 days. ↑ GSH: liver (5.4 to 8.1), kidney (3.3 to 6.0), and serum (0.8 to 2.4), restored in kidney and serum. In the brain, no effect was found. ↓ MDA: serum (13.9 to 5.9), brain (42.8 to 18.1), kidney (27.3 to 17.6), and liver (38.2 to 19.2). | [ |
| India | Decoction of the leaves (10 min) | BALB/c mice |
| At 350 and 1000 mg/kg ↓ parasitemia (73.7% and 85.8%); ↑ survival 15 and 18 days. | [ |
| India | Extraction in EtOH:H2O 50% ( | Swiss mice |
| At 300 mg/kg: ↓ infection (day 4) of the treatment, and no infection at day 19 (control group at day 24). | [ |
| Nigeria | Hidrodistillation and fractionation with ethyl acetate | ISA brown male chicks |
| At 100 mg/kg: In 10 days ↓ signs of villous collapse (stunting, matting and fusion of villi), number of wet droppings (12-6); ↑ activity, weight gaining, and feed intake (from 27 to 45 g) in contrast to the infected ones (from 30 to 18 g); ↓ bacterial shedding load (from 60 to 45 CFU/mL). | [ |
| Nigeria | Decoction of the leaves | Adult mice |
| At 250 mg/kg: Histopathological observations: mild degenerative, secretory, and inflammatory changes with goblet cells and with most of the exudate (neutrophils and lymphocytes). | [ |
| India | - | Adult male goat |
| 90 Days feeding: ↑ Hb (7.2 to 8.6 g/dL), PCV (20.2 to 29.3%), total protein (4.8 to 6.3 g/dL), GLO (2.3 to 3.8 g/dL) (↑ control (2.8)), glucose (43.9 to 52.6 g/dL), and calcium (8.7 to 9.6 mg/dL); ↓ blood urea (47.9 to 29.8 mg/dL) (↓ control (41)). Phosphorus balance, serum albumin levels and serum enzyme activity did not show variation. | [ |
Acid phosphatase (ACP); alkaline phosphatase (AKP); colony forming unit (CFU); globulin (GLO); glutathione (GSH); hemoglobin (Hb); lysozyme (LSZ); malondialdehyde (MDA); median lethal dose (LD50); nitric oxide synthase (NOS); packed cell volume (PCV); prophenoloxidase (PO); superoxide dismutase (SOD); ↑ increases the affect; ↓ decreases the effect.
In vivo studies against diseases of the blood and immune system.
| Origin | Extraction Method | Subject | Treatment | Main Results | Ref. |
|---|---|---|---|---|---|
| Nigeria | Maceration with agitation in EtOH:H2O 80% ( | Wistar rats | Treatment (1–7 days) at 150 mg/kg: ↑ Hb (6.5 to 10.7 g/dL), PCV (28.6 to 34.4%), RBCC (4.1 to 5.0 × 1012/L), MCV (53.6 to 64.3 fL), and MCHC (21.4 to 31.4 g/dL); ↓ WBC (23.2 to 19.4 × 109/dL) and neutrophil levels (28.9 to 27.3 × 103/mL).Compared to no infected subjects: similar values that obtained in treated-infected animals but with opposite conclusions. | [ | |
| Nigeria | Extraction in chloroform (24 h) | Mice | No infected | Treatment (28 days) at 45.9 mg/mL: no differences in Hb (12 to 11 g/dL), PCV (37 to 35%), RBCC (6.1 to 5.1 × 106/L), and MCHC (33 to 32 g/dL), and neutrophil levels (13 to 12%); ↑ lymphocyte levels (85 to 92%) and MCV (61 to 69 fL). | [ |
| Korea | Extraction in EtOH:H2O 55% ( | Sprague-Dawley rats and mice | Freund’s complete adjuvant-induced hyperalgesia/LPS-induced endotoxic shock | At 400 mg/kg: PWL restored; ↑ 67% survival rate (72 h) by ↓ TNF-α (500 to 325 pg/mL) and IL-6 (80 to 58 ng/mL). | [ |
| Brazil | Turbo-extraction in water and acetone: H2O 70% ( | Swiss mice | Carrageenan-induced peritonitis, acetic acid-induced abdominal writhing and hot plate test | At 50mg/kg: number of leukocyte migration into the peritoneal cavity H2O < H2O -acetone extract. No central analgesic activity. Peripheral analgesic activity: ↓ number writhing response (from 50 to 15 count). | [ |
| India | Maceration in EtOH (7 days) | Wistar rats | Acetic acid-induced writhing | At 2 mg/kg ↓ 66% number writhing response (from 67 to 54 count). Comparable to diclofenac sodium (75%). | [ |
| India | Distillation with MeOH and H2O | Wistar rats | Acetic acid-induced writhing and hot plate test | At 10 and 30 mg/kg ↓ responses time (at 9.4 and 10.6 s) compared to the analgesic drug Pentazocine (14 s). | [ |
Hemoglobin (Hb); interleukin-6 (IL-6); lipopolysaccharide (LPS); mean concentration hemoglobin count (MCHC); mean corpuscular volume (MCV); packed cell volume (PCV); paw withdrawal latency (PWL); red-blood cell counts (RBCC); tumor necrosis factor alpha (TNF-α); white-blood cell (WBC); ↑ increases the affect; ↓ decreases the effect.
Endocrine and metabolic in vivo assays with guava leaves.
| Origin | Subject | Treatment | Main Results | Ref. |
|---|---|---|---|---|
| Nigeria | Rabbits | High-cholesterol diet | At 250 mg/kg: ↓ TC (15%); ↑ HDL (69%); ↓ LDL (74%); ↓ hyperglycemia 43%. | [ |
| Brazil | Wistar rats | High-cholesterol diet | At 369.89 mg phenolic compound in the extract/g: ↓ TC (29–35%), TG (59–73%); ↑ HDL (46%); ↓ VLDL+LDL; ↓ enzyme activity (SOD (6.2 to 5.7 U/mg protein), GP (4.6 to 2.3 µmol/g protein). | [ |
| Korea | Diabetes spontaneous mutation | At 10 mg/kg: 87% inhibition PTP1B; ↓ glucose levels 31% and 42% respectively. | [ | |
| Iran | Wistar rat | Streptozotocin-induced diabetes | At 1mg/L: ↓ Ca/Mg ratio (18 to 12), glucose level, TG (100 to 65 mg/dL), TC (68 to 48 mg/dL), ↑ HDL (18 to 40 mg/dL), ↓ LDL, and VLDL to normal levels; ↓ alteration in vascular reactivity (110 to 50 mmHg). | [ |
| Taiwan | Sprague-Dawley rats | Low-dose streptozotocin and nicotinamide-induced diabetes | At 400 mg/kg: ↓ blood glucose level (230 to 140 mg/dL); ↑ plasma insulin level and glucose utilization (normal levels); ↑ enzyme activity (hepatic hexokinase (8 to 11 U/mg protein), phosphofructokinase (18 to 25 U/mg protein) and glucose-6-phosphate dehydrogenase (11 to 25 U/mg protein). | [ |
| India | Sprague-Dawley rats | Streptozotocin-induced diabetes | At 100 mg/kg: ↓ blood glucose level (4 to 1 mg/mL) and lipid peroxidation (2 to 1 mmol/100 g tissue); ↑ enzyme activity (CAT (6 to 10 × 103 U/mg protein), SOD (6 to 10 U/mg protein), GPx (0.4 to 0.6 U/mg protein), GRd (0.1 to 0.3 U/mg protein). | [ |
| Nigeria | Albino rats | Alloxan-induced diabetes | At 200 mg/kg: ↑ average weight (99 to 209g); ↓ blood glucose level (15 to 8 mmol/L); ↓ alanine aminotransferase activity (32 to 24 U/L). | [ |
| India | Albino rats | Alloxan-induced diabetes | At 500 mg/kg: ↓ blood glucose level, TC (231 to 163 mg/dL), TG (133 to 69 mg/dL), LDL (186 to 126 mg/dL), VLDL (26 to 13 mg/dL); ↑ HDL (18 to 23 mg/dL). | [ |
| Nigeria | Wister rats | - | At 150 mg/kg: ↑ ALP (300, 175and 650 IU), AST (500, 400, 450 IU), ALT (1200, 1200, 1800 IU), ACP (750, 650, 900 IU) activity in the kidney, liver, and serum, respectively. | [ |
| Nigeria | Mice | - | At 49.3 mg/mL: ↑ AST (93 to 126 iµ/L), ALT (30 to 35 iµ/L), ALP (57 to 66 iµ/L), conjugate bilirubin (0.2 to 0.3 mg/dL) and creatinine (0.9 to 1.2 mg/dL). | [ |
| Nigeria | Albino rats | - | At 150 mg/kg: ↑ serum urea (2.9 to 6 mmol/L) and creatinine (2.7 to 4 mmol/L); ↓ concentration of serum Na+ (122 to 99 mmol/L). | [ |
acid phosphatase (ACP); alanine aminotransferase (ALT); alkaline phosphatase (ALP); aspartate aminotransferase (AST); catalase (CAT); glutathione peroxidase (GPx); glutathione reductase (GRd); high-density lipoprotein (HDL) cholesterol; low-density lipoprotein (LDL) cholesterol; protein tyrosine phosphatase 1B (PTP1B); superoxide dismutase enzyme (SOD); total cholesterol (TC); triglycerides (TG); very low-density lipoprotein (VLDL) cholesterol; ↑ increases the affect; ↓ decreases the effect.
In vivo assays for digestive system related diseases.
| Origin | Extraction Method | Subject | Treatment | Main Results | Ref. |
|---|---|---|---|---|---|
| India | Extraction with MeOH | Wistar rats | ASP, PL, and EtOH-induced ulcers | At 200 mg/kg: PL-induced ulcers: ↓ 64% ulcer formation (ui = 2.1), ↓ GV (5 to 2 mL), acid secretion (88 to 64 mEq/L/100 g), ↑ pH (2 to 5).Comparable to omeprazole; ASP (↓ 70.5%, ui = 2.5) and EtOH (↓ 70.4%, ui = 8.7)-induced systems. | [ |
| Nigeria | Maceration in H2O (24 h) | Albino rats | EtOH-induced ulcers | At 1000 mg/kg: ↓ MNL (9.4 to 2) ui (4.7 to 1). | [ |
| Nigeria | Maceration with agitation in MeOH (24 h) | Wistar rats | EtOH-induced ulcers | At 1000 mg/kg: ↓ ui (17.7 to 6.3), ↑ protection (64.4%). | [ |
| India | Maceration in EtOH:H2O 90% ( | Wistar rats | PL and EtOH-induced ulcers | At 200 mg/kg: PL-induced: ↓ ulcer formation (77 to 84%), ui (5 to 1.3), GV (1.4 to 0.5 mL/100g), and acid secretion (28 to 23 mEq/L); ↑ pH (2.0 to 3.4). EtOH-induced: ↓ (63% to 79%, ui = 1.6 to 5.6), and gastric lesions (5.6–1.9). | [ |
| South Africa | Maceration in H2O (48 h) | Wistar rats and BALB/c mice | Castor oil-induced diarrhea and castor oil-induced enteropooling | At 400 mg/kg: ↑ 83.3% rat protection, ↓ 75% fluid accumulation in rats; ↓ 87.73% transit in rats and 77.2% in mice; ↓ 64.35% of contractions in mice. | [ |
| Nigeria | Soxhlet with EtOH:H2O 70% ( | Wistar rats | Castor oil-induced diarrhea | At 80 mg/kg: ↓ 53.03% transit in rats and ↓ 67.70% intestinal contractions. | [ |
| Pakistan | Maceration with EtOH | BALB/c mice, rabbit jejunum | Castor oil-induced diarrhea, K+-induced motility | At 1 g/kg: ↑ 81.1% mice protection; Spasmolytic effect (0.3–1 mg/mL) ↓ spontaneous contractions EC50 = 0.66 mg/mL in rabbits. | [ |
| India | Decoction (1 h) | Wistar rats | CCl4, PCM, and TAA-induced liver injury | At 500 mg/kg: CCl4: ↓ ALT (384 to 17 U/L), AST (642 to 152 U/L), ALP (750 to 489 U/L), and bilirubin (1.6 to 0.3 mg/dL), ↓ control levels; PCM: ↓ ALT (384 to 87 U/L), AST (642 to 179 U/L), ALP (750 to 338 U/L), and bilirubin (1.6 to 0.6 mg/dL); TAA: ↓ ALT (337 to 32 U/L), AST (438 to 237 U/L), and ALP (770 to 479 U/L). | [ |
| India | Soxhlet with EtOH | Wistar rats | PCM-induced liver injury | At 400 mg/kg: ↓ SGOT (475 to 370), SGPT (158 to 128), ALP (814 to 729), and bilirubin (0.7 to 0.6); ↑ total protein (5.15 to 5.6), albumin (2.6 to 3.1), and GLO (2.1 to 2.4). Histopathological observations: less diffuse granular degeneration and mild periportal lymphocytic infiltration. | [ |
| India | Decoction (1 h) | Wistar rats | Acetaminophen-induced liver injury | At 500 mg/kg: ↓ AST (121 to 77 IU/L), ALT (80 to 57 IU/L), ALP (115 to 67 IU/L), and total bilirubin (4 to 2 mg/dL). Restored: total protein (5 to 7 g/dL), LPO (7 to 2 nmol/mg protein), GPx (13 to 19 µmol/mg protein), GSH (15 to 23 µmol/mg protein), CAT (14 to 24 µmol/mg protein), and SOD (48 to 63 µmol/mg protein). Histopathological observations: normal lobular structure. | [ |
| Egypt | Maceration with agitation in EtOH:H2O 70% ( | Albino rats | CCl4-induced liver injury | At 500 mg/kg: ↓ ALT (94 to 55 U/mL), AST (199 to 82 U/mL), GGT (71 to 23 U/mL), lysosomal enzymes (50%), and LPO (7 to 3 nmol/mg protein); ↑ SOD (15 to 39 U/mg protein), CAT (5 to 15 µg/mg protein), GSH (6 to 8 µg/mg protein), GST (13 to 25 mM/min/mg protein), total protein (48 to 58 g/L), albumin (29 to 38 g/L), GLO (19 to 21 g/L). | [ |
| Egypt | Decoction (1 h) | Wistar rats | PCM-induced liver injury | ↓ AST (342 to 156 U/L), ALT (359 to 80 U/L), ALP (288 to 263 U/L), LDH (207 to 143 U/L), GGT (11 to 7 U/L), and total bilirubin (0.3 to 0.2 mg/dL). Restored SOD (13 to 24 U/g) and CAT (5 to 17 U/g). | [ |
Alkaline phosphatase (ALP); Alanine aminotransferase (ALT); aspirin (ASP); aspartate aminotransferase(AST); catalase (CAT); carbon tetrachloride (CCl4); ethanol (EtOH); gamma glutamyl transferase (GGT); gastric volume (GV); globulin (GLO); glutathione (GSH); glutathione peroxidase (GPx); glutathione S-transferase (GST); lactate dehydrogenase (LDH); lipid peroxidation (LPO); mean number lesions (MNL); paracetamol (PCM); pyloric ligation (PL), Serum glutamic oxaloacetic transaminase (SGOT); Serum glutamic pyruvic transaminase (SGPT), superoxide dismutase (SOD); thioacetamide (TAA); ulcer index (ui); ↑ increases the affect; ↓ decreases the effect.